Jennifer Yu Wang, MD

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Sort by

Plans whose provider directory lists this clinician

SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A144108 · Current

Licensed to practise in California · since 2016 · expires 2027-11-30 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$96,101

Medicare paid this office $96,101 for 501 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	203	$27,970	$84
Short return visit (20+ min)	212	$12,599	$51
Destruction of precancer skin growth, 1 growth	141	$8,810	$45
Long return visit (40+ min)	32	$5,677	$129
Long return visit (40+ min)	20	$5,292	$118

See all 17 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	203	$27,970	$84
Short return visit (20+ min)	212	$12,599	$51
Destruction of precancer skin growth, 1 growth	141	$8,810	$45
Long return visit (40+ min)	32	$5,677	$129
Long return visit (40+ min)	20	$5,292	$118
New patient visit (45+ min)	48	$5,193	$108
Return visit (30+ min)	33	$3,626	$79
New patient visit (60+ min)	23	$3,579	$156
Destruction of skin growth, 1-14 growths	50	$3,570	$63
Biopsy of related skin growth, first growth	102	$2,746	$22
New patient visit (30+ min)	30	$2,039	$68
New patient visit (60+ min)	11	$1,759	$160
Punch biopsy, first skin growth	36	$1,737	$46
Destruction of precancer skin growth, 2-14 growths	120	$1,351	$2
Punch biopsy, first skin growth	21	$966	$40
Biopsy of related skin growth, each additional growth	32	$815	$19
Punch biopsy, each additional skin growth	12	$343	$23

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Melanoma (skin cancer) excision	21	More than 75% of doctors who do this
Removal of skin lesions	626	More than 89% of doctors who do this
Removal or shaving of skin growth	1-10	None
Skin biopsy	303	More than 91% of doctors who do this

Who their Medicare patients are

501 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 14% · Women 50% · Also on Medicaid 12% · Health risk score 1.85. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 72% · Cancer 38% · Chronic kidney disease 28% · Coronary heart disease 27% · Diabetes 23% · Atrial fibrillation 19% · Depression 14% · Heart failure 12% · COPD 11% · Stroke 9% · Dementia 6%.

The office billed $404,525, Medicare allowed $131,994 and paid $96,101; for 2,221 services of 34 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	501	2,221	76	1.85	$404,525	$96,101
2023	560	2,483	75	1.72	$446,682	$122,794
2022	594	2,554	74	1.85	$424,394	$122,529
2021	464	2,023	73	1.96	$331,945	$95,149
2020	189	614	74	1.84	$95,126	$23,515

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 19 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	226	$33,462	$84
Short return visit (20+ min)	245	$16,516	$56
Destruction of precancer skin growth, 1 growth	138	$8,804	$46
Long return visit (40+ min)	36	$7,838	$124
Long return visit (40+ min)	26	$7,114	$129
New patient visit (45+ min)	57	$6,717	$118
Destruction of skin growth, 1-14 growths	70	$5,446	$65
Biopsy of related skin growth, first growth	147	$5,189	$26
New patient visit (60+ min)	33	$5,087	$154
Return visit (30+ min)	38	$4,500	$82
New patient visit (30+ min)	57	$4,027	$71
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm	12	$2,375	$183
New patient visit (60+ min)	15	$2,121	$141
Punch biopsy, first skin growth	47	$2,049	$39
Biopsy of related skin growth, each additional growth	53	$1,957	$20
Destruction of precancer skin growth, 2-14 growths	116	$1,212	$2
Punch biopsy, first skin growth	17	$978	$43
Short return visit	14	$447	$30
Punch biopsy, each additional skin growth	11	$324	$23

2022: 19 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	227	$33,062	$84
Short return visit (20+ min)	233	$15,250	$54
New patient visit (45+ min)	99	$11,324	$114
Destruction of precancer skin growth, 1 growth	156	$10,213	$46
Long return visit (40+ min)	38	$9,873	$122
Long return visit (40+ min)	49	$9,307	$118
New patient visit (30+ min)	80	$5,263	$66
Destruction of skin growth, 1-14 growths	67	$5,109	$60
New patient visit (60+ min)	23	$3,649	$159
Biopsy of related skin growth, first growth	134	$3,387	$22
Punch biopsy, first skin growth	63	$2,696	$40
New patient visit (60+ min)	16	$2,526	$158
Return visit (30+ min)	19	$1,744	$76
Destruction of precancer skin growth, 2-14 growths	116	$1,340	$2
Biopsy of related skin growth, each additional growth	36	$1,127	$19
Punch biopsy, first skin growth	24	$1,028	$40
Short return visit	23	$626	$26
Punch biopsy, each additional skin growth	18	$539	$23
Punch biopsy, each additional skin growth	18	$423	$23

2021: 16 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	183	$25,734	$87
Short return visit (20+ min)	172	$12,066	$54
Long return visit (40+ min)	46	$8,411	$124
New patient visit (45+ min)	67	$8,110	$121
Destruction of precancer skin growth, 1 growth	125	$8,033	$44
New patient visit (30+ min)	111	$7,291	$66
Destruction of skin growth, 1-14 growths	67	$6,356	$61
Biopsy of related skin growth, first growth	123	$3,841	$25
New patient visit (60+ min)	20	$3,402	$170
Punch biopsy, first skin growth	46	$2,033	$41
Long return visit (40+ min)	14	$2,008	$125
Short return visit	37	$1,171	$30
Biopsy of related skin growth, each additional growth	41	$1,132	$20
Destruction of precancer skin growth, 2-14 growths	99	$1,028	$2
New patient visit (15+ min)	14	$589	$42
Punch biopsy, each additional skin growth	13	$360	$24

2020: 10 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	46	$4,030	$75
Short return visit (20+ min)	58	$3,152	$48
Destruction of precancer skin growth, 1 growth	47	$2,630	$51
Long return visit (40+ min)	20	$2,256	$103
Destruction of skin growth, 1-14 growths	25	$2,086	$77
New patient visit (30+ min)	22	$1,719	$78
New patient visit (15+ min)	33	$1,479	$45
Biopsy of related skin growth, first growth	42	$1,470	$33
Biopsy of related skin growth, each additional growth	18	$599	$23
Destruction of precancer skin growth, 2-14 growths	38	$519	$2

Medicaid work

$2,734 in 2023

Medicaid paid $2,734 for 118 billed services this clinician did in 2023, up to 19 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2023

Return visit (30+ min)	93	$2,394
Short return visit (20+ min)	25	$340

Sort by

Medicaid work by year

2023	118	2	19	$2,734
2022	13	1	13	$573
2021	19	1	18	$673

See the largest Medicaid services in earlier years

2022

Sort by

Largest Medicaid services in 2022

Return visit (30+ min)	13	$573

2021

Sort by

Largest Medicaid services in 2021

Return visit (30+ min)	19	$673

Drugs they prescribed that Part D paid

$428,595

Pharmacies billed $428,595 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 696) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

635 generic and 61 brand-name prescriptions · $428,595 in drug cost · 36 antibiotic prescriptions to 23 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Cosentyx Sensoready (2 Pens)	12	$146,520	$12,210
Otezla	13	$61,852	$4,758
Dupixent	15	$56,672	$3,778
Acitretin	15	$3,905	$260
Clobetasol Propionate	40	$3,813	$95

See all 20 drugs

Sort by

Every Part D drug this clinician prescribed

Cosentyx Sensoready (2 Pens)	12	$146,520	$12,210
Otezla	13	$61,852	$4,758
Dupixent	15	$56,672	$3,778
Acitretin	15	$3,905	$260
Clobetasol Propionate	40	$3,813	$95
Triamcinolone Acetonide	111	$2,234	$20
Fluocinonide	35	$1,422	$41
Fluorouracil	20	$1,145	$57
Betamethasone Dipropionate	16	$1,110	$69
Metronidazole	13	$758	$58
Clindamycin Phosphate	17	$580	$34
Hydroxyzine	44	$494	$11
Methotrexate	17	$470	$28
Mupirocin	48	$409	$9
Betamethasone Diprop Augmented	13	$392	$30
Ketoconazole	20	$311	$16
Doxycycline Hyclate	14	$307	$22
Hydrocortisone	43	$194	$5
Gabapentin	28	$128	$5
Cephalexin	15	$92	$6

Year by year

Sort by

Part D prescribing by year

2024	696	214	0% (0)	9%	$428,595
2023	806	249	0% (0)	6%	$469,832
2022	686	227	0% (0)	9%	$309,033
2021	464	177	0% (0)	10%	$192,570
2020	97	59	0% (0)	None	$3,301
2019	30	13	0% (0)	None	$2,377
2018	14	None	0% (0)	None	$2,811

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 21 drugs

Sort by

Part D drugs prescribed in 2023

Humira	14	$104,674	$7,477
Otezla	12	$53,895	$4,491
Acitretin	14	$7,215	$515
Clobetasol Propionate	55	$4,387	$80
Fluocinonide	59	$2,951	$50
Fluorouracil	30	$2,473	$82
Triamcinolone Acetonide	127	$1,964	$15
Betamethasone Dipropionate	14	$1,435	$103
Metronidazole	11	$959	$87
Hydroxyzine	35	$769	$22
Ketoconazole	38	$701	$18
Methotrexate	25	$627	$25
Betamethasone Diprop Augmented	28	$563	$20
Clindamycin Phosphate	17	$558	$33
Doxycycline Hyclate	18	$503	$28
Mupirocin	42	$466	$11
Hydrocortisone	44	$294	$7
Gabapentin	32	$289	$9
Cephalexin	23	$262	$11
Prednisone	15	$245	$16
Ciclopirox	13	$102	$8

2022: 19 drugs

Sort by

Part D drugs prescribed in 2022

Humira	13	$89,522	$6,886
Otezla	14	$68,448	$4,889
Dupixent	13	$46,877	$3,606
Clobetasol Propionate	45	$3,341	$74
Betamethasone Dipropionate	22	$2,021	$92
Fluocinonide	41	$1,931	$47
Tacrolimus	11	$1,838	$167
Triamcinolone Acetonide	100	$1,518	$15
Fluorouracil	18	$1,289	$72
Ketoconazole	46	$1,039	$23
Hydroxyzine	21	$384	$18
Cephalexin	27	$376	$14
Mupirocin	42	$365	$9
Clotrimazole	12	$355	$30
Hydrocortisone	47	$341	$7
Methotrexate	17	$284	$17
Doxycycline Hyclate	16	$219	$14
Gabapentin	15	$135	$9
Prednisone	14	$86	$6

2021: 11 drugs

Sort by

Part D drugs prescribed in 2021

Dupixent	13	$43,628	$3,356
Otezla	11	$41,527	$3,775
Fluorouracil	19	$1,982	$104
Metronidazole	20	$1,446	$72
Fluocinonide	28	$1,393	$50
Clobetasol Propionate	31	$1,251	$40
Triamcinolone Acetonide	93	$1,238	$13
Ketoconazole	36	$717	$20
Nystatin	16	$576	$36
Mupirocin	25	$293	$12
Hydrocortisone	44	$283	$6

2020: 2 drugs

Sort by

Part D drugs prescribed in 2020

Fluocinonide	13	$681	$52
Triamcinolone Acetonide	34	$393	$12

Money from drug and device companies

$141 in 2025

Sort by

Industry payments by year

2025	1	3	None	$141
2022	1	1	$4,978	$4,978
2019	2	3	None	$55

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Sun Pharmaceutical Industries	Ilumya	$141	3 payments Meals · 2025-06-09 · $47 Meals · 2025-05-12 · $44 Meals for Ilumya · 2025-01-08 · $50

See all 3 published payments

Sort by

Every published payment

Sun Pharmaceutical Industries	Meals · 2025-06-09	None	$47
Sun Pharmaceutical Industries	Meals · 2025-05-12	None	$44
Sun Pharmaceutical Industries	Meals · 2025-01-08	Ilumya	$50

See earlier years (2022, 2019)

2022: $4,978

Sort by

Payments by company in 2022

Kyowa Kirin	Poteligeo	$4,978	1 payment Honoraria for Poteligeo · 2022-12-20 · $4,978

2019: $55

Sort by

Payments by company in 2019

Galderma Laboratories L.P.	None	$33	2 payments Meals · 2019-08-13 · $15 Meals · 2019-02-05 · $18
Regeneron Healthcare Solutions	Praluent	$23	1 payment Meals for Praluent · 2019-02-22 · $23

Professional record

NPI: 1114312329
Licence: CA A144108California A144108: Current · expires 2027-11-30
Trained: Stanford University School of Medicine, 2015
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0900X (207ND0900X)
Mailing address: 450 Broadway Street Mc 5334, Redwood City, CA, 94063
NPI first listed: 2015-04-03
NPI last updated: 2024-04-16
NPI record certified: 2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 450 Broadway Street Mc 5334, Redwood City, CA, 94063